Informations générales (source: ClinicalTrials.gov)
Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial (SUNSTAR)
Interventional
Phase 4
Lille Catholic University (Voir sur ClinicalTrials)
janvier 2018
novembre 2024
29 juin 2024
Rheumatoid arthritis (RA) is the most common inflammatory rheumatoid disease in France,
affecting 0.3% of the general population. Without effective treatment, the persistent
inflammation causes invalidating pain and joint destruction, leading to major functional
disability.
Biological agents have been proposed for patients with RA who have the most severe form
of the disease and that are inadequate responder patients to conventional synthetic
Disease-modifying antirheumatic drugs (csDMARDs). TNF inhibitors (TNFi) are historically
proposed as the first biological DAMRD for inadequate responder patients to csDMARDs. A
diverse therapeutic arsenal has become available in recent years with the development of
non-anti-TNFα drugs whose mechanisms of action are different from the classical TNFi.
This new biotherapy class includes tocilizumab and abatacept, two drugs recently
available for subcutaneous administration that enables ambulatory care for patients who
would otherwise require repeated in-hospital care.
The role of these new treatments in the therapeutic strategy has been emphasized by
studies that demonstrated their efficacy as first-line treatments. However, in clinical
practice, TNFi remain the most common first-line treatment for the majority of patients,
non-anti-TNFα biological agents being reserved for inadequate responder patients.
In second line, several studies have investigated therapeutic strategies for inadequate
responder patients to TNFi. Current data suggest that it could be wise to change the
therapeutic target after failure of a first-line treatment with TNFi.
Data about the comparative efficacy of different biologics proposed after failure of a
first-line treatment with TNFi are in progress. Meta-analyses from registries and
academic trials conducted in France and The Netherlands suggest that non-anti-TNFα agents
would have equivalent or superior efficacy compared with a second TNFi. This finding
suggests clinicians to switch for an alternate therapeutic target after failure of a
first-line TNFi.
Data comparing different non-anti-TNFα biologics in inadequate responder patients to TNFi
are scare. Industrial trials have demonstrated sustained biological efficacy of
non-anti-TNFα biologics after failure of a TNFi. However, there is very little solid data
on the direct comparison between them.
Etablissements
Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
HOPITAL NOVO | PERTUISET | 04/07/2024 11:05:06 | Contacter | ||
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
AP-HP - Hôpital Avicenne | Luca SEMERANO, MD | Contact (sur clinicalTrials) | |||
AP-HP - Hôpital Bichat | Sébastien OTTAVIANI, MD | Contact (sur clinicalTrials) | |||
AP-HP - Hôpital Cochin | Jérôme AVOUAC, MD, Pr | Contact (sur clinicalTrials) | |||
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
Ch Cahors - Cahors - France | Slim LASSOUED, MD | Contact (sur clinicalTrials) | |||
CH de Boulogne-sur-Mer - Boulogne-sur-Mer - France | Renaud DESBARBIEUX, MD | Contact (sur clinicalTrials) | |||
CH de Valenciennes - Valenciennes - France | Xavier DEPREZ, MD | Contact (sur clinicalTrials) | |||
CHD Vendée - La Roche-sur-Yon - France | Grégoire CORMIER, MD | Contact (sur clinicalTrials) | |||
CHRU de Lille - Lille - France | René-Marc FLIPO, MD, Pr | Contact (sur clinicalTrials) | |||
CHRU de Strasbourg - Strasbourg - France | Jacques-Eric GOTTENBERG, MD, Pr | Contact (sur clinicalTrials) | |||
CHU de Bordeaux - Bordeaux - France | Marie-Elise TRUCHETET, MD | Contact (sur clinicalTrials) | |||
CHU de Clermont-Ferrand - Clermont-Ferrand - France | Martin SOUBRIER, MD, Pr | Contact (sur clinicalTrials) | |||
CHU de Grenoble Hôpital Sud - Grenoble - France | Athan BAILLET, MD, Pr | Contact (sur clinicalTrials) | |||
CHU de Montpellier - Montpellier - France | Jacques MOREL, MD, Pr | Contact (sur clinicalTrials) | |||
CHU de Poitiers - Poitiers - France | Elisabeth GERVAIS, MD, Pr | Contact (sur clinicalTrials) | |||
CHU de Reims - Reims - France | Jean-Hugues SALMON, MD | Contact (sur clinicalTrials) | |||
CHU de Saint-Etienne - Saint-Étienne - France | Hubert MAROTTE, MD | Contact (sur clinicalTrials) | |||
CHU de Tours - Tours - France | Isabelle GRIFFOUL, MD | Contact (sur clinicalTrials) | |||
CHU Nice - Nice - France | Véronique BREUIL, MD, Pr | Contact (sur clinicalTrials) | |||
CHU Rouen - Rouen - France | Olivier VITTECOQ, MD, Pr | Contact (sur clinicalTrials) | |||
CHU Saint-Etienne - Saint-Étienne - France | Hubert MAROTTE, MD | Contact (sur clinicalTrials) | |||
Clinique Infirmerie Protestante de Lyon - Lyon - France | André BASCH, MD | Contact (sur clinicalTrials) | |||
Hôpital Bicêtre - Le Kremlin-Bicêtre - France | Xavier MARIETTE, MD, Pr | Contact (sur clinicalTrials) | |||
Hôpital de la Pitié-Salpêtrière - Paris - France | Bruno FAUTREL, MD, Pr | Contact (sur clinicalTrials) | |||
Hôpital Lariboisière - Paris - France | Pascal RICHETTE, MD, Pr | Contact (sur clinicalTrials) | |||
Hôpital Saint-Philibert - 59462 - Lomme - Hauts De France - France | Tristan Pascart, MD, PhD | Contact (sur clinicalTrials) |
Critères
Tous
Inclusion Criteria:
- age >18 years
- RA according to the ACR/EULAR 2010 criteria
- inadequate response to a subcutaneously administered first-line TNFi defined as
moderate to high disease activity (DAS28-ESR>3.2 and CDAI>10) after at least 3
months of treatment with a TNFi
- beneficiary of the French National Health Insurance Fund
- signed informed consent form
- for women of childbearing age: effective contraception during treatment period with
engagement to continue such contraception for 14 weeks after last administration
- age >18 years
- RA according to the ACR/EULAR 2010 criteria
- inadequate response to a subcutaneously administered first-line TNFi defined as
moderate to high disease activity (DAS28-ESR>3.2 and CDAI>10) after at least 3
months of treatment with a TNFi
- beneficiary of the French National Health Insurance Fund
- signed informed consent form
- for women of childbearing age: effective contraception during treatment period with
engagement to continue such contraception for 14 weeks after last administration
- counter-indication for one or other of the two drugs under study
- prior failure of the TNFi due to intolerance
- receiving ≥15 mg/day prednisone for more than 4 weeks
- pregnant or nursing women